Literature DB >> 3264245

Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration.

D Jung1, E Mroszczak, L Bynum.   

Abstract

The pharmacokinetics of ketorolac tromethamine, a potent non-narcotic analgesic agent used for relief of moderate to severe pain, has been studied in 15 healthy volunteers who received single 10 mg doses intravenously (i.v.), intramuscularly (i.m.) and orally (p.o.) in a three-way cross-over design. The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD). Following i.m. and p.o. administration, peak levels of approximately 0.8 microgram/ml were rapidly attained (tmax = 0.8 and 0.9 h, respectively) and the systemic bioavailability was essentially complete.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264245     DOI: 10.1007/bf00561376

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates.

Authors:  R D Brown; J E Manno
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

2.  The analgesic and anti-inflammatory profile of (+/-)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2a]pyrrole-1-carboxylic acid (RS-37619).

Authors:  W H Rooks; A J Tomolonis; P J Maloney; M B Wallach; M E Schuler
Journal:  Agents Actions       Date:  1982-12

3.  Comparison of intramuscular ketorolac tromethamine and morphine sulfate for analgesia of pain after major surgery.

Authors:  J P Yee; J E Koshiver; C Allbon; C R Brown
Journal:  Pharmacotherapy       Date:  1986 Sep-Oct       Impact factor: 4.705

4.  The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt.

Authors:  W H Rooks; P J Maloney; L D Shott; M E Schuler; H Sevelius; A M Strosberg; L Tanenbaum; A J Tomolonis; M B Wallach; D Waterbury
Journal:  Drugs Exp Clin Res       Date:  1985

5.  Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans.

Authors:  E J Mroszczak; F W Lee; D Combs; F H Sarnquist; B L Huang; A T Wu; L G Tokes; M L Maddox; D K Cho
Journal:  Drug Metab Dispos       Date:  1987 Sep-Oct       Impact factor: 3.922

6.  Synthesis and antiinflammatory and analgesic activity of 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids and related compounds.

Authors:  J M Muchowski; S H Unger; J Ackrell; P Cheung; G F Cooper; J Cook; P Gallegra; O Halpern; R Koehler; A F Kluge
Journal:  J Med Chem       Date:  1985-08       Impact factor: 7.446

  6 in total
  19 in total

Review 1.  Do the pharmacodynamics of the nonsteroidal anti-inflammatory drugs suggest a role in the management of postoperative pain?

Authors:  L E Mather
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 2.  Contemporary intravenous anesthetic agents and delivery systems: propofol.

Authors:  R M Peskin
Journal:  Anesth Prog       Date:  1992

3.  Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion.

Authors:  M Jakubowski; D Levy; V Kainz; X-C Zhang; B Kosaras; R Burstein
Journal:  Neuroscience       Date:  2007-07-25       Impact factor: 3.590

Review 4.  Ketorolac for postoperative pain management in children.

Authors:  J B Forrest; E L Heitlinger; S Revell
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

Review 5.  Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  M M Buckley; R N Brogden
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

6.  The pharmacokinetics of postoperative intravenous ketorolac tromethamine in children.

Authors:  K T Olkkola; E L Maunuksela
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

7.  Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period.

Authors:  Aida Kulo; Anne Smits; Sanita Maleškić; Marc Van de Velde; Kristel Van Calsteren; Jan De Hoon; Rene Verbesselt; Jan Deprest; Karel Allegaert
Journal:  Bosn J Basic Med Sci       Date:  2017-02-21       Impact factor: 3.363

8.  Effect of processing and sintering on controlled release wax matrix tablets of ketorolac tromethamine.

Authors:  Monica R P Rao; Anuradha A Ranpise; K C Thanki; S G Borate; G N Parikh
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

Review 9.  Clinical pharmacokinetics of ketorolac tromethamine.

Authors:  D R Brocks; F Jamali
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

10.  The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate.

Authors:  P J Hayball; J Wrobel; J G Tamblyn; R L Nation
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.